Table III.
Molecular characteristics of DLBCLs by HIV status and cell of origin*.
| Characteristic | HIV-infected cases | HIV-un infected cases | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| GCB | ABC | GCB | ABC | |||||||
|
|
|
|
|
|||||||
| n | (%) | n | (%) | p-Value† | n | (%) | n | (%) | p-Value† | |
| Total | 8 | (17)‡ | 39 | (83)‡ | 51 | (46)‡ | 60 | (54)‡ | ||
| Translocations | ||||||||||
| MYC/IgH[t(8;14)(q24;q32)] | ||||||||||
| − | 4 | (57) | 26 | (84) | 0.146 | 36 | (77) | 53 | (95) | 0.010 |
| + | 3 | (43) | 5 | (16) | 11 | (23) | 3 | (5) | ||
| IgH/BCL2[t(14;18)(q32;q2l)] | ||||||||||
| − | 8 | (100) | 33 | (100) | –** | 26 | (55) | 54 | (92) | <0.001 |
| + | 0 | (0) | 0 | (o) | 21 | (45) | 5 | (8) | ||
| BCL6/IgH[t(3;14)(q27;q32)] | ||||||||||
| − | 8 | (100) | 26 | (93) | 1.000 | 41 | (91) | 41 | (73) | 0.039 |
| + | 0 | (0) | 2 | (7) | 4 | (9) | 15 | (27) | ||
| No. of translocations§ | ||||||||||
| 0 | 4 | (57) | 18 | (72) | 0.648 | 20 | (44) | 33 | (60) | 0.009 |
| 1 | 3 | (43) | 7 | (28) | 16 | (36) | 21 | (38) | ||
| 2 or 3 | 0 | (0) | 0 | (0) | 9 | (20) | 1 | (2) | ||
| EBV | ||||||||||
| − | 7 | (88) | 10 | (26) | 0.002 | 50 | (98) | 59 | (98) | 1.000 |
| + | 1 | (13) | 29 | (74) | 1 | (2) | 1 | (2) | ||
| Primary DLBCL site | ||||||||||
| Nodal | 5 | (63) | 14 | (36) | 0.240¶ | 35 | (69) | 34 | (57) | 0.240¶ |
| Extranodal | 3 | (38) | 25 | (64) | 16 | (31) | 26 | (43) | ||
| Stomach | 0 | (0) | 4 | (10) | 2 | (4) | 7 | (12) | ||
| Lower gastrointestinal tract | 1 | (13) | 6 | (15) | 1 | (2) | 6 | (10) | ||
| Brain/central nervous system | 1 | (13) | 8 | (21) | 2 | (4) | 1 | (2) | ||
| Other | 1 | (13) | 7 | (18) | 11 | (22) | 12 | (20) | ||
DLBCL, diffuse large B-cell lymphoma; HIV, human immunodeficiency virus; ABC, activated B-cell; GCB, germinal center B-cell.
*
Cell of origin was categorized using the Tally algorithm [25] and could not be determined for four HIV+ and five HIV- patients due to missing data on CD10, GCET1, LMO2, MUM1 or FOXP1.
†
p-Value derived from Fisher's exact test.
‡
Row percentages. All other percentages reflect column percentages.
§
15 HIV+ and 11 HIV- patients with missing data for any translocation were excluded from this analysis.
¶
Compares nodal versus extranodal.
**
Statistic not calculated due to zero observed HIV+ patients with the IgH/BCL2[t(14;18)(q32;q21)] translocation.